Table 2 Post-COVID neuropsychological manifestations 12 weeks after the primary COVID-19
Symptom | Fluvoxamine (n = 42) | Placebo (n = 43) | P-value* | Relative Risk |
|---|---|---|---|---|
Primary outcome | ||||
Fatigue | 9 (21.4%) | 19 (44.2%) | 0.026 | 0.48 (0.25–0.95) |
Secondary outcome | ||||
Headache | 3 (7.1%) | 6 (14%) | 0.483 | 0.51 (0.14–1.91) |
Memory impairment | 2 (4.8%) | 5 (11.6%) | 0.433 | 0.41 (0.08–1.99) |
Poor concentration | 8 (19%) | 7 (16.3%) | 0.738 | 1.17 (0.46–2.93) |
Insomnia | 9 (21.4%) | 10 (23.3%) | 0.840 | 0.92 (0.41–2.03) |
Aggression | 1 (2.4%) | 4 (9.3%) | 0.360 | 0.25 (0.03–2.19) |
Anxiety | 8 (19%) | 13 (30.2%) | 0.232 | 0.63 (0.29–1.36) |
Depression | 1 (2.4%) | 7 (16.3%) | 0.058 | 0.14 (0.02–1.13) |
Distorted Taste | 3 (7.1%) | 8 (18.6%) | 0.115 | 0.38 (0.11–1.34) |
Distorted Smell | 6 (14.3%) | 11 (25.6%) | 0.193 | 0.56 (0.22–1.37) |
Myalgia | 5 (11.9%) | 7 (16.3%) | 0.563 | 0.73 (0.25–2.12) |
PCS | 32 (76.2%) | 35 (81.4%) | 0.557 | 0.93 (0.75–1.16) |